Needham Reiterates Buy Rating for The Oncology Institute, Inc. (TOI)
Needham maintains its buy rating for The Oncology Institute, Inc. with a $7 price target.
Key Points
- On June 17, 2026, Needham reiterated its buy rating for The Oncology Institute, Inc. (TOI) with a price target of $7.
- TOI shares traded at $5.34 with a market cap of approximately $524.9 million and a 52-week high of $5.58.
- Insider activity included planned sales by the Chief Medical Officer and purchases by another insider in recent months.
On June 17, 2026, Needham reiterated its buy rating for The Oncology Institute, Inc. (NasdaqCM: TOI), setting a price target of $7. Analyst Matthew Shea maintained the positive outlook, suggesting confidence in the company's potential.
The Oncology Institute, Inc. Stock Snapshot
Shares of NasdaqCM:TOI traded around $5.34. The Oncology Institute, Inc. has a market cap of approximately $524.9 million. The company's forward P/E ratio is not meaningful due to its current lack of profitability, reflected in its negative earnings per share of -$0.35. The stock's 52-week range spans from a low of $2.02 to a high of $5.58, with a 50-day moving average of $4.11 and a 200-day moving average of $3.56. The company shows a current ratio of 1.47 and a quick ratio of 1.13, indicating its ability to cover short-term liabilities.
Recent Earnings
The Oncology Institute reported revenue of $545.8 million, with a revenue growth rate of 41.2%. Despite this growth, the company posted a net margin of -7.97%, reflecting ongoing financial challenges. The next earnings report is expected on August 10, 2026.
Insider Buying and Selling at The Oncology Institute, Inc.
Recent insider activity at The Oncology Institute includes sales by Chief Medical Officer Yale Podnos, who sold 23,451 shares at an average price of $5.38 on June 8, 2026, under a planned transaction. Additionally, Jorey Chernett purchased 12,000 shares at $4.75 on June 4, 2026.
Analysts Set New Price Targets
On June 17, 2026, Needham maintained its buy rating for The Oncology Institute with a $7 price target. Previously, BTIG also maintained a buy rating on June 8, 2026, with a target of $8. The consensus among analysts is a strong buy, with a mean price target of $7.25 based on four analyst opinions.
About The Oncology Institute, Inc.
The Oncology Institute, Inc. is a healthcare company specializing in oncology services across the United States. Headquartered in Cerritos, California, and led by CEO Dr. Daniel Virnich, the company offers a range of services including physician care, in-house pharmacy, clinical trials, and palliative care programs. With 641 employees, the company also manages community clinics and provides educational support for cancer patients.
Bottom Line
Needham's reiterated buy rating and $7 price target for The Oncology Institute, Inc. reflect continued confidence in the company's growth prospects. Investors keep a close watch on analyst ratings as they assess the company's performance in the competitive healthcare sector. As a reminder, analyst ratings and price targets are based on past data and market conditions, and may not indicate future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.